No title
Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, with limited systemic therapeutic options and high recurrence rates. New treatment modalities in oncology, including antibody-drug conjugates and CAR-T cells, target the tumor cell surfaceome. However, despite extensive genomic and transcriptomic profiling, actionable surface antigens for targeted immunothe
